Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

2.99 (USD) • At close November 4, 2024
Bedrijfsnaam Black Diamond Therapeutics, Inc.
Symbool BDTX
Munteenheid USD
Prijs 2.99
Beurswaarde 168,949,651
Dividendpercentage 0%
52-weken bereik 1.62 - 7.66
Industrie Biotechnology
Sector Healthcare
CEO Dr. Mark A. Velleca M.D., Ph.D.
Website https://www.blackdiamondtherapeutics.com

An error occurred while fetching data.

Over Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver

Vergelijkbare Aandelen

Molecular Templates, Inc. logo

Molecular Templates, Inc.

MTEM

0.457 USD

MEI Pharma, Inc. logo

MEI Pharma, Inc.

MEIP

3.06 USD

Pro-Dex, Inc. logo

Pro-Dex, Inc.

PDEX

40.63 USD

Hepion Pharmaceuticals, Inc. logo

Hepion Pharmaceuticals, Inc.

HEPA

0.634 USD

Medicenna Therapeutics Corp. logo

Medicenna Therapeutics Corp.

MDNA

0.157 USD

Biotricity, Inc. logo

Biotricity, Inc.

BTCY

0.357 USD

Purple Biotech Ltd. logo

Purple Biotech Ltd.

PPBT

2.97 USD

Solid Biosciences Inc. logo

Solid Biosciences Inc.

SLDB

5.66 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)